# Who are Danaher Corporation's customers? Who does Danaher Corporation earn revenue from?
Canonical: https://valuechain.wiki/danaher · Facet: customers · Updated: 2026-10-09T20:24:05.807+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Danaher Corporation's confirmed revenue counterparties include 삼성바이오로직스 (싸이티바 바이오프로세싱), Moderna (Aldevron plasmid DNA) plus 2 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 4 revenue edges, backed by 8 dated sources, 4 of them primary filings (as of 2026-10-09).

### 병원·임상검사실 (진단 소모품) (high)
- metric: Revenue 9,941 USD_M · FY2025 · Diagnostics segment sales
- note: The Diagnostics segment (Cepheid, Beckman Coulter, Radiometer) supplies clinical instruments, consumables and software to hospitals, physicians' offices, reference labs and critical-care settings. FY2025 Diagnostics revenue $9.94B, the largest of the three segments, 89% recurring.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/313616/000031361626000062/dhr-20251231.htm: "The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions."
- [confirms] Danaher Investor Relations (EN, filing, published 2026-01-28) https://investors.danaher.com/2026-01-28-Danaher-Reports-Fourth-Quarter-and-Full-Year-2025-Results: "FY2025 Danaher total revenue $24.57B, Diagnostics the largest of the three segments."

### 바이오의약품 제조사 (바이오프로세싱) (high)
- metric: Revenue 7,293 USD_M · FY2025 · Biotechnology segment sales
- note: The Cytiva/Pall bioprocessing business supplies chromatography resins, filters, cell-culture media and single-use hardware/consumables to pharma, biopharma and CDMOs. FY2025 Biotechnology segment revenue $7.29B (+8.0%), 88% recurring. Cytiva is specced into >90% of global mAb production volume.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/313616/000031361626000062/dhr-20251231.htm: "The bioprocessing business' offering includes cell culture media, process liquids and buffers, chromatography resins, filtration technologies, aseptic fill finish, as well as single-use hardware and consumables. Typical users include pharmaceutical and biopharmaceutical companies, biotechnology companies and contract manufacturing organizations."
- [confirms] StockStory (EN, news, published 2025-10-23) https://stockstory.org/us/stocks/nyse/dhr/news/earnings-call/dhr-q3-2025-deep-dive-bioprocessing-diagnostics-and-productivity-initiatives-amid-policy-shifts: "Bioprocessing equipment orders grew more than 30% year-over-year, the first positive year-over-year orders growth in nearly two years."

### 삼성바이오로직스 (싸이티바 바이오프로세싱) (high)  → /samsung-biologics.md
- metric: Market share 90% · Cytiva coverage of global mAb production volume
- note: CDMOs/biomanufacturers such as Samsung Biologics use Cytiva chromatography resins (MabSelect Protein A), purification filters and cell-culture media in commercial production. Cytiva leads the Korean resin/media market. Contract values not disclosed.
- [mentions] FSS DART (KO, filing, published 2026-05-15) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658: "Danaher's Cytiva supplies bioprocessing consumables to Samsung Biologics."
- [confirms] SEC EDGAR (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/313616/000031361626000062/dhr-20251231.htm: "The bioprocessing business' offering includes cell culture media, process liquids and buffers, chromatography resins, filtration technologies, aseptic fill finish, as well as single-use hardware and consumables. Typical users include pharmaceutical and biopharmaceutical companies, biotechnology companies and contract manufacturing organizations."
- [confirms] The Korea Economic Daily (KO, news, published 2025-04-10) https://www.hankyung.com/article/202504102635i: "Cytiva Korea launched two Protein A resins (MabSelect SuRe 70 and MabSelect PrismA X) for monoclonal-antibody therapeutics. Cytiva holds the No.1 global share in purification chromatography and resins."

### 모더나 (알데브론 플라스미드 DNA) (mid)  → /moderna.md
- note: Danaher's Aldevron (acquired in August 2021 for about $9.6 billion) supplies Moderna with plasmid DNA, the template for its COVID-19 mRNA vaccine and pipeline candidates, from its GMP site in Fargo, North Dakota. The two expanded the supply agreement in May 2021. Contract value is undisclosed, and with Moderna's vaccine sales far below their 2022 peak the current volume is unknown.
- [mentions] U.S. SEC (EN, filing, published 2022-02-23) https://www.sec.gov/Archives/edgar/data/313616/000031361622000061/dhr-20211231.htm: "The Company... has expanded the business through numerous subsequent acquisitions, including... Cytiva in 2020 and Aldevron in 2021."
- [confirms] BioSpectator (KO, news, published 2021-06-18) https://m.biospectator.com/view/news_view.php?varAtcId=13444: "In May it also expanded its agreement to supply plasmid DNA to Moderna for COVID-19 vaccine production and further pipeline development. (Korean original, translated)"
- [confirms] Business Wire (EN, ir, published 2021-05-24) https://www.businesswire.com/news/home/20210524005254/en/Moderna-and-Aldevron-Announce-Expanded-Partnership-for-mRNA-Vaccine-and-Therapeutic-Pipeline: "Aldevron will provide plasmid DNA to serve as the genetic template for generating the COVID-19 mRNA vaccine and other investigational programs in Moderna's pipeline."

Reverse side: https://valuechain.wiki/danaher/suppliers.md · Ripple: https://valuechain.wiki/danaher/ripple.md

---
Full node: https://valuechain.wiki/danaher.md · JSON: https://valuechain.wiki/danaher.json